Co-Diagnostics Announces Feasibility Collaboration with ReadyGo on Blood-Based Ebola Testing
Co-Diagnostics said it is working with UK-based ReadyGo Diagnostics to evaluate whether ReadyGo's blood sample-preparation technology can work with the Co-Dx PCR platform, starting with decentralized Ebola detection. The filing describes early feasibility work only, with no financial terms, and the companies say there is no assurance the evaluation will succeed or lead to a commercially available product.
Key points
- Collaboration with ReadyGo Diagnostics Ltd. announced September 16, 2026, with an initial focus on decentralized Ebola virus detection
- Feasibility work has begun, and Co-Diagnostics has taken delivery of ReadyGo materials and devices for the evaluation
- The Co-Dx PCR platform has not been cleared or authorized by the FDA and is not yet available for sale
- Live press conference and webcast scheduled for September 16, 2026, at 10:30 a.m. ET
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.